InfuSystem Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 03, 2023 at 06:31 am EDT
Share
InfuSystem Holdings, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was USD 31.74 million compared to USD 27.04 million a year ago. Net income was USD 0.435 million compared to net loss of USD 0.164 million a year ago. Basic earnings per share from continuing operations was USD 0.02 compared to basic loss per share from continuing operations of USD 0.01 a year ago. Diluted earnings per share from continuing operations was USD 0.02 compared to diluted loss per share from continuing operations of USD 0.01 a year ago.
For the six months, sales was USD 62.11 million compared to USD 53.81 million a year ago. Net income was USD 0.111 million compared to net loss of USD 0.532 million a year ago. Basic earnings per share from continuing operations was USD 0.01 compared to basic loss per share from continuing operations of USD 0.03 a year ago. Diluted earnings per share from continuing operations was USD 0.01 compared to diluted loss per share from continuing operations of USD 0.03 a year ago.
InfuSystem Holdings, Inc. is a health care service provider that facilitates outpatient care for durable medical equipment manufacturers and health care providers. The Companyâs segments include Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services). The Companyâs core service within its ITS segment is its Oncology Business. The ITS segment supplies electronic ambulatory infusion pumps and associated disposable supply kits to private oncology clinics, infusion clinics and hospital outpatient oncology clinics to be utilized in the treatment of a variety of cancers, including colorectal cancer and other disease states. Its DME Services segments core service is to sell or rent new and pre-owned pole-mounted and ambulatory infusion pumps and other Durable Medical Equipment; sell treatment-related consumables; and provide biomedical recertification, maintenance and repair services for oncology practices as well as other healthcare site settings.
INFUSYSTEM HOLDINGS, INC. 
